Rion
Laura Becher has a diverse work experience in the field of research and biomedical sciences. Laura started their career in 2013 as a Laboratory Associate at Children's Minnesota. In 2014, they undertook multiple roles as a Summer Undergraduate Research Fellow at Mayo Clinic and as an Undergraduate Researcher at the University of North Dakota, where they worked on various projects related to amyloidosis, atmospheric and organic aerosols, and translocation-associated sarcomas. In 2015, Laura became a Graduate Student at Mayo Clinic Graduate School of Biomedical Sciences, focusing on the laboratory of Dr. Svetomir N. Markovic. Laura continued their research at Mayo Clinic as a Postdoctoral Researcher from 2020 to 2021, primarily working on the translational development of a novel nano-immunoconjugate therapeutic platform for metastatic melanoma. Currently, Laura is a Research Scientist at Rion, starting in July 2021.
Laura Becher completed their education at the Mayo Clinic Graduate School of Biomedical Sciences from 2015 to 2020. During this period, they obtained a Doctor of Philosophy (PhD) degree in Biomedical Sciences, specifically focusing on Immunology. Prior to that, from 2011 to 2015, Laura Becher attended the University of North Dakota, where they earned a Bachelor of Science (BS) degree in Chemistry and Biology.
Rion
1 followers
Rion is a clinical-stage biotechnology company That develops exosome therapeutics. Purified Exosome ProductTM (PEPTM) from Rion is a potent, useful, and easily available regenerative medicine. Research by Rion and its scientific partners has demonstrated the potential of PEP to repair a variety of injured tissue, including tendons, muscles, andskin. The goal of Rion is to spread the use of clinically effective regenerative medicine throughout the world.